To progress a lead compound from the S07 series into clinical development as a potential new treatment for leishmaniasis
current phase of drug development
updated 1 Mar 2022
This project originated from DNDi’s successful NTD Drug Discovery Booster programme. As a result of further collaboration with Takeda Pharmaceutical Company Limited to identify and advance novel compounds against visceral leishmaniasis, the S07 lead chemical series of compounds showed promising efficacy and safety profiles. DNDi and Takeda will collaborate on medicinal chemistry optimization of the S07 leads that have been identified, with the aim of progressing at least one optimized lead through to a pre-clinical candidate compound for visceral leishmaniasis, with funding support from Japan’s Global Health Innovative Technology Fund (GHIT Fund).
Get our latest news, personal stories, research articles, and job opportunities.